OMT 174
Alternative Names: OMT-174Latest Information Update: 09 Dec 2022
At a glance
- Originator OMEICOS Therapeutics
- Class Eicosanoids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mitochondrial disorders
Most Recent Events
- 07 Nov 2022 Preclinical trials in Mitochondrial disorders in Germany (PO), prior to November 2022 (OMEICOS Therapeutics pipeline, November 2022)